Mark Bouzyk, PhD will serve as the Genetics Core Director. Dr. Bouzyk is the director of the Emory Center for Medical Genomics (CMG), which will house and administer the Genetics Core. The core provides state-of-theart laboratory capabilities to enable high throughput genetic linkage and association studies ranging from candidate gene to genomic screens all supported by a robust and flexible data management infrastructure. Dr Bouzyk recently joined the faculty at Emory with a more than eight year track record in a global pharmaceutical company, GlaxoSmithKline, where he served as Director of Genetic Laboratory Sciences leading the company's high throughput genotyping efforts in Europe. During his time in industry, Dr Bouzyk not only established and managed the high throughput genetic laboratories for GSK, including DMA sample management, sequencing and genotyping, he also delivered key processes for candidate gene and whole genome association studies as well as negotiating key scientific &technological agreements for such genetic projects. This has resulted in an annual turnover of more than 10 million genotypes at GSK with significant preliminary association data in several common diseases, such as diabetes and asthma. In his position at Emory, Dr. Bouzyk serves as the link between the faculty utilizing the services of the core and the technicians analyzing the samples. Under his direction, the Center for Medical Genomics has acquired the equipment and personnel necessary to operate as a high-throughput extraction, sequencing, expression and genotyping facility. Dr. Bouzyk is responsible for working with the faculty to develop workflows for the life cycle of each project, to develop methods to ensure high quality of the data produced by the core, and to identify and acquire new technology and equipment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Center Core Grants (P30)
Project #
5P30NS055077-04
Application #
8374448
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
4
Fiscal Year
2012
Total Cost
$66,937
Indirect Cost
$23,753
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Zhang, Qi; Ma, Cheng; Gearing, Marla et al. (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathol Commun 6:19
Bay, Sarah N; Long, Alyssa B; Caspary, Tamara (2018) Disruption of the ciliary GTPase Arl13b suppresses Sonic hedgehog overactivation and inhibits medulloblastoma formation. Proc Natl Acad Sci U S A 115:1570-1575
An, Yang; Varma, Vijay R; Varma, Sudhir et al. (2018) Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimers Dement 14:318-329
Chou, Ching-Chieh; Zhang, Yi; Umoh, Mfon E et al. (2018) TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci 21:228-239
Rangaraju, Srikant; Dammer, Eric B; Raza, Syed Ali et al. (2018) Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer's disease-related proteins. Mol Neurodegener 13:34
Ping, Lingyan; Duong, Duc M; Yin, Luming et al. (2018) Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's Disease. Sci Data 5:180036
Rangaraju, Srikant; Dammer, Eric B; Raza, Syed Ali et al. (2018) Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease. Mol Neurodegener 13:24
Zhu, Dan; Osuka, Satoru; Zhang, Zhaobin et al. (2018) BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell 33:1004-1016.e5
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Umoh, Mfon E; Dammer, Eric B; Dai, Jingting et al. (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10:48-62

Showing the most recent 10 out of 256 publications